Fabrice André

Fabrice André is a leading European oncologist and translational researcher at Institut Gustave Roussy, one of Europe's top cancer centers. His research has focused on the molecular characterization of luminal B breast cancer and the development of CDK4/6 inhibitor-based therapies for hormone receptor-positive (HR+) breast cancer. He has been instrumental in large-scale genomic profiling studies that have redefined breast cancer subtypes and identified actionable alterations beyond PIK3CA mutations. André led or co-led pivotal trials including the AURORA program, a multinational metastatic breast cancer genomics initiative, and has contributed to the mechanistic understanding of why certain patients develop resistance to CDK4/6 inhibitors. His work on the ELAINE and MANTA trials exploring selective estrogen receptor degraders (SERDs) and combination strategies has helped set the direction for next-generation endocrine therapies in HR+ metastatic breast cancer. He is also a strong advocate for international collaborative science and has helped build pan-European clinical trial networks. His translational research program integrates multi-omic data with clinical outcomes to produce actionable insights, making him a central figure in shaping precision oncology standards in luminal breast cancer.